Position Statements​​

SW London Clinical Commissioning Groups (Croydon, Kingston, Merton, Richmond, Sutton and Wandsworth) do not support the routine NHS prescribing of certain medicines, in line with NHS England’s national consultation and published guidance (2017).  These medicines are items that are:

  • of low clinical effectiveness i.e. where there is a lack of robust evidence of clinical effectiveness or have significant safety concerns
  • no longer licensed in the UK
  • are clinically effective but are not cost effective for the NHS
  • are clinically effective but there are more cost effective products available
  • are available over-the-counter and inexpensive to purchase 

The NHS in SW London is currently facing a significant financial challenge and must focus its resources on the areas of greatest need.  We need to prioritise and make tough decisions to secure the future of local health services for everyone in SW London.

Please note that these position statements are subject to approval by the individual Clinical Commissioning Groups - see footers of the individual position statements for full information.

Prescriber: professional and contractual context

During discussions with the patient, when considering what treatment and ongoing monitoring is required, clinicians are asked to be mindful of the following:

  • that within their Primary Medical Services contract with NHS England, GPs have a contractual obligation relating to patients with chronic disease to make available such treatment (including any prescription deemed to be appropriate after discussion with the patient) as is necessary and appropriate, and to provide advice in connection with the patient's health, including relevant health promotion advice
  • that reference to local prescribing guidelines is good professional practice
  • that consideration of GMC professional obligations to use NHS resources wisely is good professional practice

For the Position Statement for prescribing preparations available to buy over the counter (OTC) for self-care and related documents, please click here.

  
  
SWL Glucosamine PIL FINAL V1 July 2017.pdf
  
SWL Position statement aliskiren FINAL V2 Feb 20.pdf
  
SWL Position statement amiodarone Final V1 April 2018.pdf
  
SWL Position statement antifungal nail FINAL V2 November 2017.pdf
  
SWL Position statement antihistamine and nasal sprays for hayfever FINAL V3 May 2018.pdf
  
SWL Position statement Bath and Shower Emollients FINAL V1 Dec 2019.pdf
  
SWL Position statement Calogen FINAL V1 April 2020.pdf
  
SWL Position statement camouflages Final V1 June 2019.pdf
  
SWL Position Statement cannabis sativa FINAL V1 Jan 2018.pdf
  
SWL Position statement complementary and alternative medicine FINAL V2 January 2018.pdf
  
SWL Position statement co-proxamol FINAL V2 January 2018.pdf
  
SWL Position statement coughs and colds FINAL V3 May 2018.pdf
  
SWL Position statement Diabetic Needles Final V1 July 2020.pdf
  
SWL Position statement dosulepin FINAL V2 January 2018.pdf
  
SWL Position statement doxazosin modified release tablets FINAL V2 January 2018.pdf
  
SWL Position statement dronedarone FINAL V1 Feb 2020.pdf
  
SWL Position statement fentanyl immediate release FINAL V1 March 2018.pdf
  
SWL Position statement glucosamine FINAL V2 glucosamine January 2018.pdf
  
SWL Position statement haemorrhoids FINAL V3 May 2018.pdf
  
SWL Position statement infant colic FINAL V3 May 2018.pdf
  
SWL Position statement lidocaine patches Final V1 May 2018.pdf
  
SWL Position statement liothyronine Final V2 June 2020.pdf
  
SWL Position statement minocycline Final V2 Dec 2019.pdf
  
SWL Position statement ocular supplements FINAL V2 January 2018.pdf
  
SWL Position statement omega 3 fatty acids Final V1 April 2019.pdf
  
SWL Position statement once daily tadalafil Final V1 May 2018.pdf
  
SWL Position statement perindopril arginine FINAL V2 January 2018.pdf
  
SWL Position statement probiotics FINAL V3 Jan 19.pdf
  
SWL Position statement products for dental conditions FINAL V2 May 2018.pdf
  
SWL Position statement rubefacients FINAL V4 February 2018.pdf
  
SWL Position statement silk garments Final V2 Dec 2019.pdf
  
SWL Position statement Targinact FINAL V1 Jan 2018.pdf
  
SWL Position statement Tramacet  FINAL V2 January 2018.pdf
  
SWL Position statement travel vaccines FINAL V2 January 2018.pdf
  
SWL Position statement trimipramine FINAL V1 July 2018.pdf
  
SWL Position statement vitamin D FINAL V2 August 2018.pdf
  
SWL Position statement vitamins and minerals FINAL V1 May 2018.pdf
  
SWL Position statements version control log 100720.pdf